AstraZeneca Announces Phase III WAYPOINT Trial of Tezspire (tezepelumab) Meets Primary Endpoints in Chronic Rhinosinusitis with Nasal Polyps

AstraZeneca(AZN.US) announced that the Phase III WAYPOINT study of Tezspire (tezepelumab) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) met the co-primary endpoints. The results showed that the Tezepelumab treatment group demonstrated statistically significant and clinically meaningful reductions in nasal polyps and relief of nasal congestion symptoms.

Public information shows that Tezepelumab is a drug developed by AstraZeneca andAmgenA first-in-class monoclonal antibody jointly developed to inhibit thymic stromal lymphopoietin (TSLP). TSLP is a key epithelial cytokine located upstream of multiple inflammatory cascades and is associated with diseases such as asthma, CRSwNP, chronic obstructive pulmonary disease (COPD), and eosinophilic esophagitis (EoE). Tezspire can block TSLP, thereby preventing immune cells from releasing pro-inflammatory cytokines, achieving therapeutic effects for related diseases.

It is reported that Tezepelumab has been approved in the United States for the treatment of severe asthma and is currently undergoing Phase III clinical trials in China. In addition to CRSwNP, Tezepelumab is also being developed for other potential indications, including COPD and EoE.

Editor: Guo Mingyu